TP53 and cancer: Pleasingly, nearly all of the metallohelices in Table 2 (enantiomers of 10, 11, Δ-12, Δ-14 and racemic-4 (ref. 15 and 37)) are at least as active in HCT116 cells which do not express p53 (HCT116 p53−/−); the p53 tumour suppressor gene is one of the most frequently mutated in cancer, and is commonly ascribed to increased resistance to chemotherapeutic drugs.